Table 2 Correlation between PD-L1 protein expression by immunohistochemistry and variable clinicopathologic parameters in 167 HER2-positive breast cancers

From: Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value

 

PD-L1 expression on tumour cells by Allred scoring system

p-value

PD-L1 expression on TILs

p-value

Total PD-L1 expression on tumour cells and TILs

p-value

Negative (Number (%))*

Positive (Number (%))*

Low (Number (%))*

High (Number (%))*

Low (Number (%))*

High (Number (%))*

Age (years), mean ± SD**

52.94 ± 10.26

52.21 ± 10.02

0.642

52.84 ± 10.76

52.00 ± 8.58

0.621

52.49 ± 10.73

52.79 ± 8.77

0.859

Size (cm), mean ± SD**

3.130 ± 2.047

3.300 ± 1.434

0.538

3.187 ± 1.626

3.271 ± 2.086

0.590

3.27 ± 2.010

3.07 ± 1.100

0.848

Side

  

0.353

  

0.616

  

0.504

Right

51 (59.3)

42 (51.9)

 

63 (54.3)

30 (58.8)

 

61 (53.5)

32 (60.4)

 

Left

35 (40.7)

39 (48.1)

 

53 (45.7)

21 (41.2)

 

53 (46.5)

21 (39.6)

 

Histologic grade

  

<0.001

  

0.001

  

<0.001

Grade 1, 2

43 (50.0)

19 (23.5)

 

53 (45.7)

9 (17.6)

 

54 (47.4)

8 (15.1)

 

Grade 3

43 (50.0)

62 (76.5)

 

63 (54.3)

42 (82.4)

 

60 (52.6)

45 (84.9)

 

Nuclear grade

  

0.227

  

0.120

  

0.192

Grade 1, 2

18 (20.9)

11 (13.6)

 

24 (20.7)

5 (9.8)

 

23 (20.2)

6 (11.3)

 

Grade 3

68 (79.1)

70 (86.4)

 

92 (79.3)

46 (90.2)

 

91 (79.8)

47 (88.7)

 

Necrosis

  

0.256

  

1.000

  

0.489

Absent

33 (38.4)

24 (29.6)

 

40 (34.5)

17 (33.3)

 

41 (36.0)

16 (30.2)

 

Present

53 (61.6)

57 (70.4)

 

76 (65.5)

34 (66.7)

 

73 (64.0)

3 (69.8)

 

Lymphovascular invasion

  

0.062

  

0.012

  

0.007

Absent

40 (46.5)

50 (61.7)

 

55 (47.4)

35 (68.6)

 

53 (46.5)

37 (69.8)

 

Present

46 (53.5)

31 (38.3)

 

61 (52.6)

16 (31.4)

 

61 (53.5)

16 (30.2)

 

Lymph node metastasis

  

0.758

  

0.503

  

0.507

Absent

39 (45.3)

39 (48.1)

 

52 (44.8)

26 (51.0)

 

51 (44.7)

27 (50.9)

 

Present

47 (54.7)

42 (51.9)

 

64 (55.2)

25 (49.0)

 

63 (55.3)

26 (49.1)

 

Stage

  

0.722

  

0.340

  

0.256

Early (stage I, II)

66 (76.7)

60 (74.1)

 

85 (73.3)

41 (80.4)

 

83 (72.8)

43 (81.1)

 

Advanced (stage III, IV)

20 (23.3)

21 (25.9)

 

31 (26.7)

10 (19.6)

 

31 (27.2)

10 (18.9)

 

HR expression

  

0.217

  

0.044

  

0.001

Positive

50 (58.1)

39 (48.1)

 

68 (58.6)

21 (41.2)

 

71 (62.3)

18 (34.0)

 

Negative

36 (41.9)

42 (51.9)

 

48 (41.4)

30 (58.8)

 

43 (37.7)

35 (66.0)

 

TILs level***

  

<0.001

  

<0.001

  

<0.001

≤10%

46 (53.5)

15 (18.5)

 

57 (49.1)

4 (7.8)

 

58 (50.9)

3 (5.7)

 

20–60%

36 (41.9)

38 (46.9)

 

49 (42.2)

25 (49.0)

 

47 (41.2)

27 (50.9)

 

>60%

4 (4.7)

28 (34.6)

 

10 (8.6)

22 (43.1)

 

9 (7.9)

23 (43.4)

 

TLSs around DCIS

  

0.112

  

0.493

  

0.307

Low

58 (67.4)

44 (54.3)

 

73 (62.9)

29 (56.9)

 

73 (64.0)

29 (54.7)

 

High

28 (32.6)

37 (45.7)

 

43 (37.1)

22 (43.1)

 

41 (36.0)

24 (45.3)

 

TLSs around invasion

  

0.002

  

0.034

  

0.057

Low

66 (76.7)

43 (53.1)

 

82 (70.7)

27 (52.9)

 

80 (70.2)

29 (54.7)

 

High

20 (23.3)

38 (46.9)

 

34 (29.3)

24 (47.1)

 

34 (29.8)

24 (45.3)

 
  1. *except for age and sizes. **The t-test was performed and the equality of variances was assumed. SD, standard deviation. ***The linear-by-linear association was carried out. The Pearson’s Chi-square test or Fisher’s exact test was used as appropriate for the other variable.
Back to article page